There have been 35 insider transactions in the 90-day period previous to the date of this filing from the activities of 7 individual insiders all of which have been purchases and resulted in the acquisition of 4,178,250 company shares. Relative to the preceding 90-day window of time, there were 16 transactions from 2 insiders that resulted in the net acquisition of 734,232 shares.
This level of insider activity is near the average number of transactions experienced in the 150-company Pharmaceuticals peer group over the last 90-day period. Activity in the peer group averaged 35.1 transactions per company, and with company insiders disposing of 7,127 company shares on average.
SEC Story Link http://www.sec.gov/Archives/edgar/data/944809/000120919119033769/xslF345X03/doc4.xml
|Aevi Genomic Medicine In Deal with Astellas to Devel...|
|Insider Trends: Insider at CareDx Converts Options i...|
|Close Update: US Stocks Struggle for Direction, Clos...|
|Arbutus Biopharma Reports No Major Negative Effects ...|
|Arrow Electronics Preliminary Q2 Disappoints on Weak...|